Literature DB >> 5570509

[Epidemiology of muscoviscidosis in children in Poland].

K Bozkowa, H Gol ebiowska, J Rutkowski, A Nowakowska, J Holzer.   

Abstract

Entities:  

Mesh：

Year:  1971        PMID： 5570509

Source DB:  PubMed          Journal:  Pediatr Pol        ISSN： 0031-3939


× No keyword cloud information.
  6 in total

1.  Analysis of most common CFTR mutations in patients affected by nasal polyps.

Authors:  Marzena Kostuch; Janusz Klatka; Andrzej Semczuk; Jacek Wojcierowski; Lucas Kulczycki; Jan Oleszczuk
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-06-17       Impact factor: 2.503

2.  Newborn screening for cystic fibrosis: Polish 4 years' experience with CFTR sequencing strategy.

Authors:  Agnieszka Sobczyńska-Tomaszewska; Mariusz Ołtarzewski; Kamila Czerska; Katarzyna Wertheim-Tysarowska; Dorota Sands; Jarosław Walkowiak; Jerzy Bal; Tadeusz Mazurczak
Journal:  Eur J Hum Genet       Date:  2012-08-15       Impact factor: 4.246

3.  Frequency of the cystic fibrosis mutation delta F508 in Poland.

Authors:  J Bal; D Maciejko; T Mazurczak; A Potocka; M Krawczak; J Reiss
Journal:  Hum Genet       Date:  1991-01       Impact factor: 4.132

4.  Carrier status for 3 most frequent CFTR mutations in Polish PCD/KS patients: lack of association with the primary ciliary dyskinesia phenotype.

Authors:  Urszula Skrzypczak; Ewa Rutkiewicz; Andrzej Pogorzelski; Michał Witt; Ewa Zietkiewicz
Journal:  J Appl Genet       Date:  2007       Impact factor: 2.653

5.  A cross-sectional study of growth, nutritional status and body proportions in children and adolescents at a medical center specializing in the treatment of cystic fibrosis in Poland.

Authors:  Dorota Sands; Wioleta Umławska; Anna Zielińska
Journal:  Arch Med Sci       Date:  2015-03-14       Impact factor: 3.318

6.  CFTR mutations spectrum and the efficiency of molecular diagnostics in Polish cystic fibrosis patients.

Authors:  Ewa Ziętkiewicz; Ewa Rutkiewicz; Andrzej Pogorzelski; Barbara Klimek; Katarzyna Voelkel; Michał Witt
Journal:  PLoS One       Date:  2014-02-26       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.